Botulinum toxin: Bioweapon & magic drug

Ram Kumar Dhaked, Manglesh Kumar Singh, Padma Singh & Pallavi Gupta

Biotechnology Division, Defence Research & Development Establishment, Gwalior, India

Botulinum neurotoxins, causative agents of botulism in humans, are produced by Clostridium botulinum, an anaerobic spore-former Gram positive bacillus. Botulinum neurotoxin poses a major bioweapon threat because of its extreme potency and lethality; its ease of production, transport, and misuse; and the need for prolonged intensive care among affected persons. A single gram of crystalline toxin, evenly dispersed and inhaled, can kill more than one million people. The basis of the phenomenal potency of botulinum toxin is enzymatic; the toxin is a zinc proteinase that cleaves neuronal vesicle associated proteins responsible for acetylcholine release into the neuromuscular junction. As a military or terrorist weapon, botulinum toxin could be disseminated via aerosol or by contamination of water or food supplies, causing widespread casualties. A fascinating aspect of botulinum toxin research in recent years has been development of the most potent toxin into a molecule of significant therapeutic utility. It is the first biological toxin which is licensed for treatment of human diseases. In the late 1980s, Canada approved use of the toxin to treat strabismus, in 2001 in the removal of facial wrinkles and in 2002, the FDA in the United States followed suit. The present review focuses on both warfare potential and medical uses of botulinum neurotoxin.

Key words Botulism - botulinum toxin - Clostridium botulinum - neurotoxin - proteinase

Introduction

Clostridium botulinum and botulism, the disease it causes, have been known to man for centuries. Botulism is a severe neuroparalytic disease caused by the action of botulinum neurotoxins (BoNTs) produced by anaerobic spore-forming C. botulinum and some of its close relatives. The BoNTs are regarded as the most potent toxins known to mankind. If left untreated, a severe case of botulism leads to death of the patient due to paralysis of respiratory muscles. Although the disease has been known to man since ancient time, Muller in 1870 coined the name ‘botulism’ for the newly described disease. Following the advent of microbiology in the late 19th century, the causative organism was isolated from contaminated meat and recognized as an anaerobic bacillus. Cultivation of the bacillus and its subsequent introduction into animals leading to development of the symptoms of botulism has been reported.

One of the most fascinating aspects in the field of botulinum toxin research in recent years has been application of the most potent toxin in treatment of neurological disorders. It has become the first biological toxin which is licensed as drug for treatment of human diseases. As of January 2008, two BoNT serotypes (A and B) are approved for clinical use in the United
States by Food and Drug Administration (FDA). Subsequently, the neurotoxin has become a household name as clients line up at local gyms, parties, and spas for Botox injections, in order to temporarily rid themselves of wrinkles and sweaty armpits. This review provides updated information on warfare potential and medical uses of botulinum neurotoxin.

**Botulism: Disease**

All four forms of botulisms (food borne, infant, wound and animal) cause illness through a common pathway regardless of the manner in which the toxin gains systemic access. Botulism initiates with acute weakness of muscles, causing difficulty in speaking and swallowing and double with blurred vision in all forms of diseases. This is followed by a progressive asymmetrical flaccid paralysis, descending from the muscles of the head and throat, which in severe cases causes death due to respiratory muscles paralysis. Mental functioning is not impaired by BoNTs, so the patient remains alert and conscious throughout the disease. Botulism is confirmed by detection of BoNT in a patient’s serum or stool, or in a sample of food consumed before onset of illness.

Food-borne botulism is also known as “classical” botulism, as it was the first form of the disease described in literature. Food poisoning due to botulinum toxin emerged as a problem when food preservation became a widespread practice. BoNT is secreted in to food by toxigenic clostridia growing in it under suitable conditions. Ingestion of preformed toxin is responsible for the botulism thus this type of disease represents intoxication rather than an infection, which is the case of other form of human botulism. In a study of 2622 outbreaks in which BoNT types were determined, 34 per cent were caused by type A, 52 per cent by type B and 12 per cent by type E. Only two food borne outbreaks were assigned to BoNT type F during this period. More than 90 per cent cases of foodborne botulism have been reported due to home prepared or home preserved foods. A wide variety of commercially produced (preserved and non-preserved) foods have caused botulism outbreaks. Examples include foil-wrapped baked potatoes, canned chili sauce, jars of peanuts, packed food, hazelnut yogurt, garlic in oil, carrot juice, and matambre (Argentine meat roll).

Infant botulism, recognized as a clinical identity over three decades ago, has been the most diagnosed form of botulism in USA since 1979. The initial neurological symptoms of infant botulism are largely the same as in other forms of botulism, but these are usually missed by parents and doctors because the infant can not verbalize them. The case/fatality ratio among hospitalized patients was reported to be less than one per cent. The source of spores for most cases remains unknown, although the most common sources of infection for infants appear to be honey and environmental exposure. Analysis of infant botulism cases occurring globally from 1996 through 2008 revealed 524 cases in 26 countries representing five continents.

Another form of botulism is analogous to tetanus, in that BoNT is determined from *C. botulinum* growing *in vivo* in abscessed wounds called wound botulism. Most cases occur in physically active young males who are presumable at higher risk of traumatic injuries. Wound botulism has emerged as a small-scale epidemic in San Francisco, USA, among Bay Area drug abusers following subcutaneous injection of heroin. Similarly, in the United Kingdom, bacterial infections (particularly wound botulism) have increased markedly since 2000 among injecting heroin users. Some cases have also been reported in Germany and in Sweden, where real-time PCR was used to diagnose a case of type E wound botulism. The case/fatality ratio has been rather high (15%).

Most mammals are susceptible to botulinum neurotoxin and develop botulism with similar clinical features to humans. A majority of cases are caused by *C. botulinum* group III, although groups I and II are also reported in animal botulism. Horses are very sensitive to BoNTs and equine botulism occurs sporadically worldwide, both as feed poisoning and as toxico-infectious forms. Avian botulism is usually caused by BoNT type C1, to which most birds seem to be susceptible. Botulism is very dangerous in fish farming. Contaminated silage has been reported to cause botulism outbreaks among cattle.

Inhalational botulism is not a natural form of botulism and most likely to be seen on the battlefield, is rare. One incident involving accidental exposure of humans to BoNT/A in a laboratory of Germany was reported in 1961. More data are available on exposure of animals to toxin aerosols. Rhesus monkeys were exposed by inhalation to BoNT/A, in conjunction with toxoid and hyperimmune globulin efficacy trials. Park and Simpson reported that BoNT/A, an inhalation poison, works by the active process of binding and transcytosis across airway epithelial cells.
Iatrogenic botulism is caused inadvertently by injection of botulin toxin for therapeutic or cosmetic reasons. Four cases of iatrogenic botulism occurred in December 2004 in Florida following cosmetic injection with a botulin toxin that was not approved for use in humans.

Botulism in Indian scenario

Food-borne botulism is thought to be an uncommon clinical condition in India and is rarely reported. First incidence of food borne botulism in India was reported in 1996 involving 34 students with two deaths and toxigenic C. butyricum was isolated. Two patients of one family (42 yr old man and his 6 yr old daughter) consumed canned meat products were diagnosed clinically according to CDC guidelines as botulism. Dhaked et al. isolated toxigenic clostridia from soil of slaughter house, of which one was confirmed by PCR and mouse protection assay as C. botulinum type E. Prevalence and distribution of C. botulinum was also studied in fish from coastal and inland areas of India. Types A to D were found to be present on sediments, surface of wild fish and intestine with dominance of C. botulinum type C and D. Recently, multiplex PCR for the detection of C. botulinum and C. perfringens toxin genes was reported on eight suspected food borne botulism cases.

Clostridium botulinum: Bacterium

Bacteria isolated from the outbreaks of the beginning of the century were not all similar to the Van Ermengem’s strain. The clinical manifestations of the intoxication were all alike, but the cultural characteristics and growth requirement of different isolates differed. By cross neutralization tests of their respective toxins the different C. botulinum isolates were divided into two types, A and B. Bacteria were also isolated from animal botulism cases in 1920 and were designated as type C and D. Thereafter, a serotype E was isolated from fish food. Moller & Scheibel isolated serotype F and Gimenez & Ciccarelli serotype G, respectively from a Danish patient and Argentinean soil. Thus, seven distinct serotypes of botulin toxin have now been isolated, designated A through G. That means one serotype has been isolated approximately every 12 years since Van Ermengem’s original isolation. Serotypes A, B, E and F have been clearly identified in numerous human poisoning episodes. Serotype G has only been identified in a few outbreaks. Serotypes C and D have been found in outbreaks involving various animals. Why humans are typically not poisoned by serotypes C and D is not clear.

Early chromosomal DNA-DNA homology studies showed that the single species decision did not hold up to modern nucleic acid based taxonomical scrutiny and later C. botulinum was divided into three groups I to III. This decision was validated through 16S ribosomal RNA sequence analysis. The non-disease forming serotype G, found at the time of grouping was termed as C. botulinum group IV by Smith & Hobbs, but has subsequently been given a species name of its own, Clostridium argentinens. It has been recognized that the botulinum neurotoxins are produced by four distinct groups of C. botulinum based on cultural and biochemical properties or DNA-DNA homology. However, in 1986, it was demonstrated that two clostridial species other than C. botulinum produced botulin toxin in three cases of infant botulism, two in Rome, Italy and one in New Mexico. Type BoNT/F producing C. butyricum was isolated from the cases in Rome and BoNT/F producing C. baratii from the infant botulism case in New Mexico. Generally a single organism expresses a single toxin type but some strains of C. botulinum are also reported to be capable of producing mixtures of two types of toxin, such as A+F, A+B or B+F. In addition, strains that possess unexpressed, ‘silent’ genes have also been reported.

Whole genome sequences of various C. botulinum strains along with their plasmids are available in the GenBank depositories. Total 17 C. botulinum complete genomes have been sequenced (till Oct, 2009), which include representatives of all the serotypes excepting C. botulinum type G. These genomes provide an excellent opportunity for comparative analysis of C. botulinum and will undoubtedly provide valuable insights into the pathogenicity, metabolic diversity and evolution of these organisms.

Botulinum neurotoxins

Botulinum neurotoxins are the most poisonous poison known to the humankind produced by strains of C. botulinum. The lethal dose for a person by the oral route is estimated at 30 ng, by the inhalational route 0.80 to 0.90 µg, and by the intravenous route 0.09 to 0.15 µg. Assuming an average weight of 70 kg each of 5.6 billion people, only 39.2 g of pure BoNT would be sufficient to eradicate humankind. Due to their absolute neurospecificity these neurotoxins do not react with any substrates in the presynaptic motor neurons, BoNTs are extremely toxic. The two most
likely mechanisms for use of botulinum toxin as a terrorist weapon include deliberate contamination of food or beverages or via an aerosol release. In type A, three different sized progenitor toxins with molecular masses of 900 kDa (19 S, LL toxin), 500 kDa (16 S, L toxin) and 300 kDa (12 S, M toxin) were observed. Types B, C and D strains produce both 16 S and 12 S toxins, whereas types E and F produce 12 S toxins and type G produces only 16 S toxin. Therefore, it was postulated that 19 S and 16 S toxins have both haemagglutinin (HA) and non-toxin non-haemagglutinin (NTNH) proteins whereas 12 S toxin is formed by association of NTNH protein only.

The neurotoxin is released as a single polypeptide chain of 150 kDa, which is later nicked to generate two disulphide linked fragments, the heavy chain (H, 100 kDa) and light chain (L, 50 kDa) (Fig.). The H chain is responsible for binding, internalization and membrane translocation, whereas L chain for target modification in the cytosol. The function of L chains has been established as zinc dependent endopeptidases, and the substrates are one of the three proteins of the docking complex responsible for release of acetylcholine from synaptic vesicles. Light chain of types A, C and E acts on SNAP 25 and VAMP/ synaptobrevin is cleaved by BoNT B, D, F and G along with tetanus neurotoxin whereas syntaxin is cleaved by BoNT/C. BoNT is internalized in cholinergic nerve endings and remain in the presynaptic motor neurons causing flaccid paralysis.

**Characterization and detection of Clostridium botulinum and their toxins**

Basic principal of detection and isolation of *C. botulinum* from clinical, food and environmental samples has remained essentially unchanged since E Van Ermengem’s first report, more than a century ago. Isolation of *C. botulinum* almost invariably starts with anaerobic enrichment of the samples in a non selective culture media, e.g. Robertson cooked meat medium (CMM) or trypticase-peptone-yeast extract-glucose (TPYG) broth for 3-10 days at 26-35°C. Usually culture are heat (70°C for 10 min) or ethanol treated (50 % for 1 h) prior to plating to get rid off vegetative cells which greatly improves subsequent isolation. Although selective media for *C. botulinum* have been developed, their use has remained limited. The efficiency of selection in the media has been questioned, since antibiotics used seems to inhibit some strains of type E and to alter the appearance of type G colonies.

The optimal and minimal growth temperatures for group I strains is 35-40 and 10°C, for group II strains 18-25 and 3.3°C, and for group III strains 40 and 15°C, respectively. The cells of all strains of *C. botulinum* are straight to slightly curved sporulating, anaerobic bacilli with round ends, measuring 2 to 20 μM in length and 0.5 to 2 μM in width. The spores are oval and sub-terminal and usually swell to occupy the sporangium. The spores are resistant to heat, desiccation, chemicals, radiation and oxygen which facilitate their survival for very long periods. Most cultures retain Gram stain well, becoming Gram-negative only after sporulation or during late stationary phase.

It is thought that since *C. botulinum* is an anaerobic organism, it will be unable to grow in foods which are exposed to oxygen or in foods which do not have a low oxidation-reduction potential (Eh). Actually, the Eh of the food exposed to oxygen is low enough in most of the food to permit the growth of *C. botulinum*. Even though the maximum growth occurs at an Eh of -350 mV, *C. botulinum* can grow at Eh values as high as +250 mV. A substantial body of research has shown no growth of *C. botulinum* at pH 4.8 or lower and led to the current government regulation that canned foods at pH 4.6 or lower would be safe without conventional methods required by legislation.

---

**Fig.** The di-chain structure of a botulinum neurotoxin A (BoNT/A). Botulinum neurotoxins are ~150-kDa proteins, synthesized as single-chain polypeptides and post-translationally nicked to form di-chain molecules. They share the same domain architecture and overall structure. The light and heavy chains of BoNT/A are linked by a single disulphide bond, Cys430–Cys454. The light chain, shown in red, functions as zinc-dependent endopeptidase. The heavy chain comprises two functional domains of roughly equal size. The N-terminal section, shown in blue, is the translocation domain and is thought to be involved in translocation and activation of the LC. The C-terminal section, shown in green, is acting as binding domain.
sterilization. One of the first definitive attempts to influence water activity \((a_w)\) was performed by Denny et al.\(^\text{96}\) and reported that the growth of \(C.\ botulinum\) type A and B was dependent on \(a_w\) of canned bread and not on moisture content. No toxin was produced in canned breads stored up to two years with \(a_w\) values \(\leq 0.950\). Emodi & Lechowich\(^\text{97}\) found that the minimum \(a_w\) for the growth of type E ranges from 0.972 to 0.978 in a wide variety of solutes. The minimum \(a_w\) values for the growth of types A and B in food is 0.94 and for type E is 0.97 corresponding to a sodium chloride concentration of 10 and 5 per cent, respectively.

Identity of \(C.\ botulinum\) and other BoNT producing clostridia is confirmed by toxin detection. Table I lists detection limits, field applicability and the types of samples for which BoNT assays were demonstrated.

In outbreaks of botulism, it is customary to assay suspected foods, patient’s sera, faeces samples and enrichment cultures for the presence of toxin\(^\text{91}\). Half ml of undiluted toxin preparation with same amount of 1:2, 1:10 and 1:100 diluted antisera in gelatin phosphate buffer should be intra-peritoneally injected in pairs of 15-20 g mice. Through incorporation of serotype testing by Leuchs\(^\text{46}\) and Burke\(^\text{47}\), the method has evolved present day form, the mouse bioassay\(^\text{88}\). The second stage of the mouse lethality test is to identify the serological toxin type by mouse protection assay with specific monovalent (types A-G) antisera. Universally acknowledged for detecting biological activity of BoNTs in samples, the mouse bioassay, although is highly sensitive, has been criticized as being slow, laborious, expensive and lacking in specificity. Furthermore, the increasing public resistance to animal testing makes it clear that there is a need to replace bioassay with reliable \textit{in vitro} test\(^\text{109}\). Recovery of \(C.\ botulinum\) from stools or gastric samples with symptoms and signs indicative of botulism is usually sufficient for confirmation. Recovery of the organism from food that does not contain demonstrable toxin is inconclusive. Electrophysiological studies can provide a presumptive diagnosis of botulism in patients with clinical signs of botulism\(^\text{110}\) and can be especially helpful when laboratory tests are negative.

Numerous attempts were made to replace mouse bioassay with immunological based methods \textit{i.e.}, fluorescent antibody test\(^\text{111}\), immunodiffusion\(^\text{112}\), fiber optic biosensor\(^\text{113}\), streptavidin-biotin amplified ELISA\(^\text{114}\) and ELCA (enzyme linked coagulation assay) amplified ELISA\(^\text{115}\). Some of these methods are sensitive enough and used in some laboratories for screening samples, however, any of these methods is so far not authorized for official or clinical use due to

---

**Table I. Performance of existing botulinum toxin assays**

| Assay                      | Type of toxin | Time of the assay | Detection limit | Potential for field Diagnostics* | Sample type                          |
|---------------------------|---------------|-------------------|-----------------|----------------------------------|--------------------------------------|
| Mouse neutralization assay\(^\text{94}\) | A, B, C, D, E, F, G | 1-4 days         | 20-30 pg/ml     | ++                               | Foods, serum and stool                  |
| TRF\(^\text{96}\)          | A, B          | 2 h               | 20-200 pg/ml.   | +                                | Clinical/environmental samples       |
| Fluorometric Biosensor\(^\text{99}\) | A, B         | uncertain         | ?               | +/-                              | Aassay buffer and live cells          |
| Modified ELISA\(^\text{100}\) | A, B, E, F   | 6 h               | 0.6 ng/ml       | ++                               | Liquid and solid foods, serum        |
| Micromechanosensor\(^\text{101}\) | B             | 15 min            | >8 nM           | ++                               | Sample buffer                         |
| Mass Spectometry MALDI-TOF-MS/Endopeptidase-MS\(^\text{102}\) | A, B, E, F   | 4 - 16 h          | 5 pg/ml or lower | +/-                              | Milk, serum and stool extract        |
| BoNT ALISSA\(^\text{103}\) | A             | 2-3 h             | 0.5 fg/ml       | ++                               | Serum, milk, carrot juice, gelatin and phosphate diluents |
| Immuno-PCR\(^\text{104}\) | A, B, E       | 4 - 6 h           | 50 fg/ml        | +/-                              | Carbonate buffer                      |
| Liposome PCR assay\(^\text{105}\) | A             | 6 h               | 0.2 fg/ml       | +/-                              | Carbonate buffer                      |
| Enzyme-amplified protein microarray immunoassay\(^\text{106}\) | A             | 10 min            | 1.4pg/ml        | +                                | Blood and plasma                      |
| SPR\(^\text{107}\)         | B, F          | 5 min             | 0.1 pg/ml       | +/-                              | Assay buffer                          |
| Ganglioside-liposome immunoassay\(^\text{108}\) | A             | 20 min            | 15pg/ml         | +/-                              | Assay buffer                          |

*Potential for field diagnostics: ++ high, +intermediate, +/- low*
to their inability to differentiate active and inactive neurotoxin\textsuperscript{109}. Recently, PCR-ELISA has been used for the study of prevalence of \textit{C. botulinum} type A, B, E and F in fish and environmental samples in northern France\textsuperscript{110}. In another attempt, extreme biological specificity of the BoNTs for proteins VAMP, SNAP25, etc., in the nerve cells, has been utilized in a novel ‘second generation’ ELISA, the endopeptidase assay\textsuperscript{117}. Attempts are also being made to develop sensitive endopeptidase assay utilizing small fluorogenic peptide substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F\textsuperscript{118}.

PCR-based methods\textsuperscript{119} detecting the botulinum neurotoxin (BoNT) gene was pioneered to replace the time consuming conventional methods and mouse bioassay. Since then different workers\textsuperscript{120-125} have applied this technique for the detection of BoNT genes in epidemics, environmental samples screening and epidemiological prevalence studies. Lindstrom et al\textsuperscript{126} have described and detected four BoNT genes namely types A, B, E and F by multiplex PCR.

The first report about genomic characterization of \textit{C. botulinum} was published in 1995 and included MRP analysis of four type A strains by pulsed field gel electrophoresis (PFGE)\textsuperscript{127}. Hielm et al\textsuperscript{128} described the use of PFGE in genomic analysis of group II \textit{C. botulinum} and found it to be highly discriminating and reproducible. However, not all strains were typeable either due to DNA degradation by active endonucleases or resistance of the cell wall to lysis. The application of rRNA gene restriction pattern analysis (ribotyping) for the genomic characterization of \textit{C. botulinum} groups I and II strains has also been reported\textsuperscript{129}. However, the discriminatory power was found to be lower than that of PFGE and there were some difficulties in the interpretation of patterns generated by certain restriction enzymes. Therefore, ribotyping was concluded to be suitable only for taxonomic purposes in \textit{C. botulinum} species identification.

**Protection against botulinum neurotoxin**

Since the reported cases of all forms of botulism are rare, vaccination for general population is not warranted on the basis of cost and expected adverse reactions with even the best vaccines. Moreover, vaccination against BoNT will restrict its therapeutic and cosmetic applications in the subjects. There are two basic alternatives for prophylaxis of high risk individuals from botulinum poisoning; active immunization using a vaccine, or passive immunotherapy using immunoglobulin. In cases of wound botulism, the wound should be surgically debrided and antibiotics should be administered (usually penicillin). A pentavalent crude toxoid vaccine (A-E) and a singular F toxoid are investigational drugs distributed by the CDC to military and research workers that might come into contact with toxin\textsuperscript{130}. Since these have not acquired FDA approval, these toxoid vaccines are not licensed for general distribution. The impetus to meet FDA requirements is low, because these vaccines require frequent boosters and are toxic due to the formaldehyde used to inactivate the toxins\textsuperscript{131}. Efficacy of the pentavalent botulinum toxoid (PBT) was evaluated and antibodies concentrations were found to be significantly higher (≥ 0.25 U) in 99 per cent of the 508 military personnel vaccinated before and after Persian Gulf War\textsuperscript{132}.

Even though toxoid vaccines are available, there are numerous shortcomings with their current use\textsuperscript{133}. (i) \textit{C. botulinum} being sporiferous, a dedicated facility is required; (ii) yields of toxin production are very low; (iii) the toxoiding process involves large quantities of toxin and thus dangerous; (iv) toxoid proteins are not purified thus other proteins may influence immunogenicity or reactivity of the vaccine; and (v) since the residual levels of formalin are part of the product formulation to prevent reactivation of toxin, the vaccine is reactogenic. The development of a new generation recombinant vaccine could alleviate many of the problems associated with the toxoid. So the alternative approaches to develop vaccines against the botulinum neurotoxins are currently being pursued by several laboratories. Attassi & Oshima\textsuperscript{134} have synthesized a series of overlapping 19 mer peptides that spawned the entire Hc region of BoNT/A and reported as vaccine candidate. Lee et al\textsuperscript{135} introduced a gene fragment encoding non-toxic Hc region of BoNT/A into Venezuelan equine encephalitis virus replicon vector to yield high levels of Hc that protected mice against a $10^5$ LD\textsubscript{50} challenge of BoNT/A. Byrne et al\textsuperscript{136} expressed the region of BoNT/A in \textit{Pichia pastoris} and recombinant BoNT/A Hc prevented botulinum intoxication. Immunization of mice with three doses of 1 µg heavy chain of BoNT/B was fully protective when mice were challenged with 10\textsuperscript{6} LD\textsubscript{50} BoNT/B after 1 year of vaccination\textsuperscript{133}. DNA vaccine\textsuperscript{137} fused with signal peptide could protect mice against 10\textsuperscript{4} MLD challenge of BoNT/F. Recently, a single dose of adenovirus-vectorised vaccine molecules derived from heavy chain of type C are reported to provide protection against botulism\textsuperscript{138,139}.
Antitoxin therapy\textsuperscript{140} is more effective if undertaken early in the course of illness. The only antitoxins available are equine antitoxin from CDC (neutralizing antibodies against BoNT/A, /B, and /E) and an investigational heptavalent (against ABCDEFG) antitoxin. BabyBIG\textsuperscript{®}, derived from the blood of human donors vaccinated with a pentavalent (ABCDE) toxoid vaccine, is only available for infant botulism\textsuperscript{141}. This is not surprising when one considers that equine antitoxin neutralizes only toxin molecules yet unbound to nerve endings\textsuperscript{142}. More than 80 per cent of persons reported with adult botulism in the United States are treated with antitoxin. However, treatment is not without risk, as approximately 9 per cent of persons treated experience hypersensitivity reactions\textsuperscript{143}. A human-derived botulism antitoxin, termed “botulism immune globulin”\textsuperscript{144}, has been prepared, and a clinical trial of its efficacy when given early in the course of illness is in progress in California.

**Molecular inhibitors against neurotoxin**

The BoNT molecule is divided in clear functional domains that can operate independently. This feature provides multiple targets for designing therapeutics to treat botulism. Therapeutics against BoNT can target any of the three steps of mode of action of BoNT: binding, endocytosis/translocation, and endopeptidase activity. Humanized monoclonal antibodies, small peptides, peptide mimetics, receptor mimics, and small molecules targeting active sites are candidates for inhibiting botulinum toxin and may eventually be used in treatment strategies. Studies reported that toosendanin\textsuperscript{145-147} (major limonoid constituent of the bark of the tree *M. toosendan*) could protect monkeys from BoNT/A, BoNT/B, and BoNT/E-induced death in a dose dependent fashion when co-administered with, or several hours after, neurotoxin administration. A semisynthetic strategy to identify inhibitors based on toosendanin, has been reported by Fischer *et al.*\textsuperscript{148} to protect from BoNT intoxication.

Based on the substrate information, several small peptides have been developed as competitive inhibitors for the BoNT endopeptidase activity. Peptidomimetics and hydroxamic acid-based inhibitors have been developed that display inhibitory effects\textsuperscript{149-152} in the high nm range for the light chain of the BoNT serotype A.

Many drug-like small molecule libraries are available commercially as well as in national repositories. Screening these drug-like compounds has become critical in finding new therapeutic candidates. Screening such libraries requires a robust assay feasible for the high throughput screening. Such assays have been developed for screening the endopeptidase activity of BoNT\textsuperscript{156,157}, making it feasible to find inhibitors against the protease activity of BoNT by screening large library of compounds.

Another target to design antagonists against botulism is to block the binding between BoNTs and their receptors. Cai *et al.*\textsuperscript{153} have demonstrated that the quinic acid can inhibit the binding between HcQ and the ganglioside at the concentration of 10 mM. While receptor mimics are valid targets for designing inhibitors against the botulism, like antibody based therapy, the treatment window for such agents is short, since they can only target at the circulation level. Once the toxin gets internalized into the nerve cells, effectiveness of receptor-based inhibitors will be very limited.

Aptamers form unique structures that provide basis for high affinity and specificity towards their targets (proteins or the small molecules). Their specific and tight interactions serve as valuable tools to modulate or block functions of proteins. The screening process for aptamers is popularly termed as SELEX (Systematic Evolution of Ligands through EXponential enrichment). An efficient and easy-to-execute single microbead SELEX approach is developed to generate high affinity ssDNA aptamers against botulinum neurotoxin\textsuperscript{154}.

Targeting extracellular neutralization and binding of BoNT to cell surface will provide effective prophylactic treatment and prevention measures to botulism. An effective BoNT-based drug delivery vehicle can be used to directly deliver toxin inhibitors into intoxicated nerve terminal cytosol to reverse the paralysis. Recently, amino dextran based drug delivery vehicle has been reported to deliver BoNT-A antidotes into BoNT-A intoxicated cultured mouse spinal cord cells\textsuperscript{155}. This approach can potentially be utilized for targeted drug delivery to treat other neuronal and neuromuscular disorders.

**BoNTs as magic drug**

One of the most fascinating aspects on *C. botulinum* in recent years has been development of the most potent toxin into a molecule of significant therapeutic utility. Purified protein derived from the bacterium *C. botulinum* type A was originally developed about three decades ago by US scientists for medical use\textsuperscript{156,157}. BoNT is the first bacterial toxin licensed by USFDA as ‘occulinum’ a drug for the treatment of blepharospasm
in 1989. Botox® (from Allergan), minute amount of purified BoNT/A, is the only botulinum toxin treatment to have undergone the rigorous approval process in 15 countries required to secure a license for the treatment of facial wrinkles. This holds a unique position in that it is a safe and effective medical treatment for a number of highly distressing conditions, while also being used as a cosmetic therapy where there is no underlying medical condition. Lately, BoNT/B\textsuperscript{158} and BoNT/F\textsuperscript{159} were also successfully used to prevent muscles hyperactivity. As of January 2008, two BoNT serotypes (A and B) are approved for clinical use in the United States by Food and Drug Administration (www.fda.gov). A carefully purified and defined quantity of the botulinum neurotoxin is injected by a trained surgeon within the spastic muscle which considerably reduce presynaptic outflow of acetylcholine at the neuromuscular junction, with a consequent diminution in muscle hyperactivity/contraction, while leaving some strength for the physiological function. A basal rate of acetylcholine secretion across the synaptic cleft occurs continuously, with each packet of acetylcholine depolarizing the post-synaptic membrane to create miniature end plate potentials (MEPPs). MEPPs summate to maintain the motor end-plate potential (EPP). Botulinum neurotoxins prevent acetylcholine secretion, reducing the frequency and quantity, but not amplitude of MEPPs. The motor EPP is reduced below the muscle membrane threshold and the ability to generate muscle fiber action potentials and subsequent contraction is diminished\textsuperscript{160}. These toxins are safe drugs. One reason is that upon injection the protein does not diffuse beyond 2 cm, exerting its paralyzing activity around the injection site with very limited spreading. Several pharmaceutical preparations of botulinum toxins for the treatment of human diseases in ophthalmology, neurology and dermatology are currently marketed under the trade names Botox®, Dysport® and Xeomin® (based on botulinum neurotoxin A), and Myoblock® / Neuroblock® (based on botulinum neurotoxin B)\textsuperscript{161-163}. With the exception of Xeomin, which is practically devoid of complexing proteins\textsuperscript{164}, the other commercial formulations of botulinum toxins include, besides the neurotoxin, other bacterial complexing haemagglutinins and nonhaemagglutinin proteins as well. Several additional substances (e.g., albumin, sucrose, lactose) are included in these preparations and aim at drug stabilization and facilitation of administration by intramuscular injection. In lyophilized form the toxins may be kept in long storage; however, if diluted with saline for injection, these must be used within a few hours. The biological potency of these preparations is expressed in mouse units. One mouse unit is defined as the intraperitoneally injected quantity of each pharmaceutical product required to kill 50 per cent (LD\textsubscript{50}) of an experimental group of female Swiss-Webster mice, each of 20 g body weight. The US FDA has approved use of these preparations in cervical dystonia, blepharospasm, spasmodic, torticollis, strabismus and glabellar frown lines. These are being used in approximately 150 different indications, e.g., disorders of ocular motility, writer’s cramp, hemi facial spasm and spasticity, achalasia, chronic anal fissure and hyperhidrosis (Table II). The new uses for this ‘wonder drug’ are under constant evaluation, including gastrointestinal smooth muscles and skeletal muscle spasm following CNS injury, cosmetic management of wrinkles\textsuperscript{170} and debarking of dogs\textsuperscript{179}. One vial of Botox contains 100 units (U) of purified neurotoxin complex produced by C. botulinum type A, 0.5 mg of albumin (human), and 0.9 mg of sodium chloride in a sterile, vacuum-dried form without a preservative. The lethal dose of the Botox preparation for a person of 70 kg is calculated to be 2,500-3,000 units. The recommended

| Table II. Uses of botulinum neurotoxin |
|----------------------------------------|
| **Indication**                        | **Example**                                      |
| Dystonias\textsuperscript{165}        | Cervical dystonia, Oromandibular dystonia, Pharyngolaryngial dystonias, Jaw closure/opening dystonias, Occupational cramps, Limb and axial dystonias |
| Spasticity\textsuperscript{166}       | Cerebral palsy, Brain injury, Spinal cord injury |
| Eyelid spasm\textsuperscript{167}     | Blepharospasm, Hemifacial spasm, Eyelid twitch |
| Exocrine gland hyperactivity\textsuperscript{164} | Focal hyperhidrosis, Relative sialorhrea, Crocodile tears syndrome, |
| Movement disorders\textsuperscript{169} | Tremors, Bruxism, Tic |
| Pain syndromes\textsuperscript{170}   | Migraine, Back spasm |
| Urinary bladder dysfunction\textsuperscript{171} | Sphincter- detrusor dyssnergia, detrusor hyperreflexia, |
| Ophthalmology\textsuperscript{172}   | Strabismus, Entropion, Protective ptosis |
| Cosmetology\textsuperscript{173}     | Hyperactive facial lines-brow lines, Frown lines, |
| Gastroenterology\textsuperscript{174} | Achalasia, Anal fissures, Anismus |
| Gynecology\textsuperscript{175}      | Vaginismus |
| Urology\textsuperscript{176}         | Sterile prostatitis |
| Dentistry\textsuperscript{177}       | Muscle spasm associated with temporomandibular joint pathology |
| Veterinary\textsuperscript{178}      | Barking dogs |
The ability of BoNTs to transport large polypeptides across neuronal and non-neuronal origin is an outstanding problem. Additionally, the ability of BoNTs to transport large polypeptides across the membranes could be harnessed for the delivery of biopharmaceuticals to cytosolic targets. Derivatives of BoNT/A and BoNT/B can target compounds specifically to human neuroblastoma cells. The therapeutic potential of clostridial toxins is not limited to the neurotoxin for the inhibition of neurotransmitter release, but also has potential as an anticancer drug. The technology termed ‘clostridia directed enzyme pro-drug therapy’ (CDEPT) in which intravenously injected clostridial spores are used to target hypoxic regions of solid tumours. Spores get localized to solid tumours exclusively for germination, as they cannot grow in healthy tissues. Genetic modification of the clostridial host to express anti cancer compounds or pro-drug converting enzymes (as in CEDPT), has the potential to lead the localized destruction of solid tumour tissue.

**Future directions**

Although some progress has been made in recent years, identification and characterization of the protein receptors for the BoNTs and determination of the mechanism of specificity of CNT binding domains for their receptors is an outstanding problem. Further, understanding the mechanism of LC translocation and activation within the motorneuron, including the effects of pH on the tertiary structures of BoNTs, will be crucial for rational design of engineered BoNT therapeutics. Further structural studies on the endopeptidase domains of BoNTs, including the structural basis behind BoNT substrate specificity, might lead to the development of serotype-specific inhibitors.

It has been proposed that the extreme neurospecificity of BoNT heavy chains could be applied to deliver engineered molecule in to nerve cells. This can be achieved by the replacement of light chain with desired therapeutic agent that could be reached in the nerve endings without iatrogenic complications which might otherwise occur. Use of fragments of BoNT for the therapeutics of the future is also exciting. For example, harnessing the properties of the BoNT LC endopeptidase fragments for the creation of a range of ‘designer’ therapeutics is a real possibility following the successful retargeting of the LC/A domain to cells of neuronal and non-neuronal origin. Additionally, the ability of BoNTs to transport large polypeptides across the membranes could be harnessed for the delivery of biopharmaceuticals to cytosolic targets. Derivatives of BoNT/A and BoNT/B can target compounds specifically to human neuroblastoma cells. The therapeutic potential of clostridial toxins is not limited to the neurotoxin for the inhibition of neurotransmitter release, but also has potential as an anticancer drug. The technology termed ‘clostridia directed enzyme pro-drug therapy’ (CDEPT) in which intravenously injected clostridial spores are used to target hypoxic regions of solid tumours. Spores get localized to solid tumours exclusively for germination, as they cannot grow in healthy tissues. Genetic modification of the clostridial host to express anti cancer compounds or pro-drug converting enzymes (as in CEDPT), has the potential to lead the localized destruction of solid tumour tissue.

**References**

1. Bigalke H, Shoer LF. In: Aktories K, Just I, editors. Clostridial neurotoxins: Handbook of experimental pharmacology. Berlin: Springer Verlag: 2001. p. 407-47.
2. Hatheway CL. Clostridium botulinum and other Clostridia that produce botulinum neurotoxins. In: Hauschild AHW, Dodds KL, editors. Clostridium botulinum: Ecology and control in foods. New York: Marcel Dekker; 1992. p. 3-20.
3. Lamanna C. The most poisonous poison. Science 1959; 130: 763-72.
4. Dolman CE. Botulism as a world health problem. In: Lewis KH, Kassel Jr. K, editors. Botulism. Cincinnati: Ohio: U.S. Department of Health, Education, and Welfare. Public Health Service; 1964. p. 5-32.
5. Van Ermengem, E. About a new anaerobic bacillus and its relationship to botulism. Z Hyg Infektionskr 1897; 26: 1-56.
6. Bengston IA. Studies on organisms concerned as causative factors in botulism. Hyg Lab Bull 1924; 136: 101.
7. Midura TF. Update: infant botulism. Clin Microbiol Rev 1996; 9: 119-25.
8. Hughes JM, Blumenthal JR, Merson MH, Lombard GL, Dowell VR Jr., Gangarosa EJ. Clinical features of type A and B food-borne botulism. Ann Intern Med 1981; 95: 442-5.
9. Hatheway CL. Botulism: the present status of the disease. Curr Top Microbiol Immunol 1995; 195: 55-75.
10. Hatheway CL. Botulism. In: Balows A, Hausler WH, Ohashi M, Turmano A, editors. Laboratory Diagnosis of Infectious Diseases: Principles and Practice, vol. 1. New York: Berlin Heidelberg, Springer; 1988. p. 111-33.
11. Haushchild AHW. Epidemiology of human foodborne botulism. In: Haushchild AHW, Dodds KL, editors. *Clostridium botulinum*. Ecology and Control in foods. New York: Marcel Dekker; 1992. p. 68-104.

12. Angulo FJ, Gez J, Taylor JP, Hendricks KA, Hatheway CL, Barth SS, et al. A large outbreak of botulism: the hazardous baked potato. *J Infect Dis* 1998; 178 : 172-7.

13. Centers for Diseases Control (CDC). *Botulism associated with canned chili sauce*. Atlanta: CDC; 2007 July-Aug.

14. Chou JH, Hwang PH, Malison MD. An outbreak of type A foodborne botulism in Taiwan due to commercially preserved peanuts. *Int J Epidemiol* 1988; 17 : 899-902.

15. Kalluri P, Crowe C, Reller M, Gaul L, Hayslett J, Barth S, et al. An outbreak of foodborne botulism associated with food sold at a salvage store in Texas. *Clin Infect Dis* 2003; 37 : 1490-5.

16. O’Mahony M, Mitchell E, Gilbert RJ, Hutchinson DN, Begg NT, Rodhouse JC, et al. An outbreak of foodborne botulism associated with contaminated hazelnut yoghurt. *Epidemol Infect* 1990; 104 : 389-95.

17. St Louis ME, Peck SH, Bowering GB, Bltherwick J, Banerjee AK, Crowe C, et al. Wound botulism associated with black tar heroin among drug users in the United Kingdom. *Brett MM, Hood J, Brazier JS, Duerten BI, Hahn SJ. Soft tissue infections caused by spore-forming bacteria in injecting drug users in the United Kingdom. Epidemiol Infect 2005; 133 : 575-82.

18. Steth AN, Wiersma P, Atrubin D, Dubey V, Zink D, Skinner G, et al. International outbreak of severe botulism with prolonged toxemia caused by commercial carrot juice. *Clin Infect Dis* 2008; 47 : 1245-51.

19. Villar DG, Shapiro RL, Bustos S, Riva-Posse C, Verdejo G, Farace MI, et al. Outbreak of type A botulism and development of a botulism surveillance and antitoxin release system in Argentina. *JAMA* 1999; 281 : 1334-8.

20. Midura TF, Arnon SS. Infant botulism: Identification of *Clostridium botulinum* and its toxin in feces. *Lancet* 1976; 2 : 934-6.

21. Shapiro RL, Hatheway CL, Swerdlow DL. Botulism in the United States: A clinical and epidemiological review. *Ann Intern Med* 1998; 129 : 221-8.

22. Arnon SS. Human tetanus and human botulism. In: Rood JI, Shapiro RL, Hatheway CL, Swerdlow DL, editors. *Botulinum and tetanus Neurotoxins and Biomedical aspects*. New York: Plenum Press; 1993. p. 473-6.

23. Park JB, Simpson LL. Inhalational poisoning by botulinum toxin and inhalational vaccination with its heavy chain component. *Infect Immun* 2003; 71 : 1147-54.

24. Chertow DS, Tan ET, Maslanka SE, Schulte J, Bresnitz EA, Weissman RS, et al. Botulism in 4 adults following cosmetic injections with an unlicensed highly concentrated botulinum preparation. *JAMA* 2006; 296 : 2476-9.

25. Chaudhry R, Dhawan B, Kumar D, Bhatai R, Gandhi JC, Patel RK, et al. Outbreak of suspected *Clostridium botulinum* botulism in India. *Emerg Infect Dis* 1998; 4 : 506-7.

26. Agarwal AK, Goel A, Kohli A, Rohtagi A, Kumar R. Foodborne botulism. *J Assoc Physicians India* 2004; 52 : 677-8.

27. Lalitha KV, Surendran PK. Occurrence of *Clostridium botulinum* in fresh and cured fish in retail trade in Cochin (India). *Int J Food Microbiol* 2002; 72 : 169-74.

28. Joshy L, Chaudhry R, Chandel DS. Multiplex PCR for the detection of *Clostridium. botulinum* & *C. perfringens* toxin genes. *Indian J Med Res* 2008; 128 : 206-8.
46. Leuchs J. Contributions to the knowledge of the toxin and antitoxin of Bacillus botulinus. Ztschr Hyg Infektskh 1910; 65: 55-84.

47. Burke GS. Notes on Bacillus botulinus. J Bacteriol 1919; 4: 555-65.

48. Seddon HR. Bulbar paralysis in cattle due to the action of toxicogenic bacillus, with a discussion on the relationship of the condition to forage poisoning (botulism). J Comp Pathol Therap 1922; 35: 147-90.

49. Thieler A, Viljoen PR, Green HH, du Toit PJ, Meier H, Robinson EM. Lamsiekte (parabotulism) in cattle in South Africa. 11th and 12th Report of Director Veterinary Education and Research Part II, Sect. 5 Department of Agriculture, Union South Africa; 1927. p. 1201-11.

50. Gunnnson JB, Cummings JR, Meyer KF. Clostridium botulinum type E. Proc Soc Exp Biol Med 1953; 35 : 278-80.

51. Moller V, Scheibel I. Preliminary report on the isolation of an apparently new type of Clostridium botulinum. Acta Pathol Microbiol Scand 1960; 48 : 80.

52. Gimenez DF, Ciccarelli AS. Another type of Clostridium botulinum. Zentralbl Bakteriol Prasiten kd Infektionskr Hyg Aft 1 Orig 1970; A215: 221-4.

53. Lee WH, Reimann H. The genetic relatedness of proteolytic Clostridium botulinum strains. J Gen Microbiol 1970; 64: 85-90.

54. Holdeman LV, Brooks JB. Variations among strains of Clostridium botulinum and related clostridia. In: Herzberg M, editor. Proceedings of the First US-Japan conference on toxigenic microorganisms. Washington: US Government Printing Office; 1970. p. 278-86.

55. Hutson RA, Thompson DE, Lawson PA, Schocken-Itturino RP, Bottger EC, Collins MD. Genetic interrelationships of proteolytic Clostridium botulinum types A, B, and F and other members of Clostridium botulinum complex as revealed by small-subunit rRNA gene sequences. Antonie van Leeuwenhoek 1993; 64: 273-83.

56. Hutson RA, Thompson DE, Collins MD. Genetic interrelationships of saccharolytic Clostridium botulinum types B, E and F and related clostridia as revealed by small-subunit rRNA gene sequences. FEMS Microbiol Lett 1993; 108: 103-10.

57. Collins MD, Lawson PA, Willems A, Cordoba JJ, Fernandez-Garayzabal J, Garcia P, et al. The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. Int J Syst Bacteriol 1994; 44: 812-26.

58. Smith LDS, Hobbs G. Genus III. Clostridium prazmowskii 1980, 23. In: Buchanan RE, Gibson NE, editors. Bergey's manual of determinative bacteriology, 8th ed. Baltimore: Williams & Wilkins; 1974. p. 551-72.

59. Suen JG, Hatheway CL, Steigerwald AG, Brenner DJ. Clostridium botulinum sp. nov: A genetically homogenous group composed of all strains of Clostridium botulinum toxin type G and some non-toxicigenic strains previously identified as Clostridium subterminale or Clostridium hastiforme. Int J Syst Bacteriol 1988; 38: 375-81.

60. Aureli P, Fencia L, Pasolini B, Gianfranceschi M, McCroskey LM, Hatheway CL. Two cases of type E infant botulism in Rome caused by neurotoxicogenic Clostridium botulinum. J Infect Dis 1986; 154: 207-11.

61. Hall JD, McCroskey LM, Pinkomb BJ, Hatheway CL. Isolation of an organism resembling Clostridium beratti which produce type F botulinum toxin from an infant with botulism. J Clin Microbiol 1985; 21: 654-5.

62. Minton NP. Molecular genetics clostridial neurotoxins. Curr Top Microbiol Immunol 1995; 195: 161-95.

63. Brinkac LM, Daugherty S, Dodson RJ, Madupu R, Brown JL, Bruce D, et al. Complete sequence of Clostridium botulinum strain Langeland/NCTC10281/Type F Submitted to the EMBL/GenBank/DDBJ databases. 2007 JUN.

64. Brinkac LM, Brown JL, Bruce D, Detter C, Munk C, Smith LA, et al. Complete sequence of Clostridium botulinum strain type B Ekland. Submitted to the EMBL/GenBank/DDBJ databases. 2008 APR.

65. Sebahia M, Peck MW, Minton NP, Thomson NR, Holden MTG, Mitchell WJ, et al. Genome sequence of a proteolytic (Group I) Clostridium botulinum strain Hall A and comparative analysis of the clostralid genomes. Genome Res 2007; 17: 1082-92.

66. Smith TJ, Hill KK, Foley BT, Detter JC, Munk AC, Bruce DC, et al. Analysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids. PLoS ONE. 2007; 2: E1271-E1271.

67. Shrivastava S, Brinkac LM, Brown JL, Bruce D, Detter CC, Johnson EA, et al. Genome sequence of Clostridium botulinum A2 Kyoto. Submitted to the EMBL/GenBank/DDBJ databases. 2008 OCT.

68. Shrivastava S, Brown JL, Bruce D, Detter C, Munk C, Smith LA, et al. Genome sequence of Clostridium botulinum Ba4 strain 657. Submitted to the EMBL/GenBank/DDBJ databases. 2008 MAY.

69. Peck MW. Clostridium botulinum and the safety of minimally heated, chilled foods: an emerging issue? J Appl Microbiol 2006; 101: 556-70.

70. Schiavo G, Rossetto O, Tonello F, Montecucco C. Intracellular target and metalloprotease activity of tetanus and botulinum neurotoxins. Curr Top Microbiol Immunol 1995; 195: 257-74.

71. Villar RG, Elliot SP, Davenport KM. Botulism: the many faces of botulism toxin and its potential for bioterrorism. Infect Dis Clin N Am 2006; 20: 313-27.

72. Sugii S, Sakaguchi G. Molecular construction of Clostridium botulinum type A toxins. Infect Immun 1975; 12: 1262-70.

73. Inoue K, Fuginaga Y, Watanabe T, Oshyama T, Takeda K, Morishii K, et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect Immun 1996; 64: 1589-94.

74. Chen F, Kuziemco GM, Stevens R. Biophysical characterization of the stability of the 150-Kilodalton botulinum toxin, the non-toxic component and the 900-Kilodalton botulinum toxin complex species. Infect Immun 1998; 66: 2420-5.

75. Sakaguchi G, Kozaki S, Ohnishi I. Structure and function of botulinum toxins. In: Alouf JE, Fehrenbach FJ, Freer JH, Jeljaszewics J, editors. Bacterial protein toxins. London: Academic Press; 1984. p. 435-43.

76. Montecucco C, Schiavo G. Mechanism of action of tetanus and botulinum neurotoxins. Mol Microbiol 1994; 13: 1-8.
108. Ahn-Yoon S, DeCory TR, Durst RA. Ganglioside–liposome immunoassay for the detection of botulinum toxin. *Anal Bioanal Chem* 2004; 378 : 68-75.

109. Wictome M, Shone CC. Botulinum neurotoxins: Mode of action and detection. *J Appl Microbiol* 1998; 84 : S87-97.

110. Cherington M. Clinical spectrum of botulism. *Muscle Nerve* 1998; 21 : 701-10.

111. Glasby C, Hatheway CL. Fluorescent-antibody reagents for the identification of *Clostridium botulinum*. *J Clin Microbiol* 1983; 18 : 1378-83.

112. Lilly T, Kautter DA, Lynt RK, Solomon HM. Immunodiffusion detection of *Clostridium botulinum* colonies. *J Food Prot* 1984; 47 : 868-75.

113. Ogert RA, Brown JE, Singh BR, Shriver-Lake LC, Ligler FS. Detection of *Clostridium botulinum* toxin A using a fiber optic-based biosensor. *Anal Biochem* 1992; 205 : 306-12.

114. Ekong TAN, McLellan K, Sesardic D. Immunological detection of *Clostridium botulinum* type A in therapeutic preparations. *J Immunol Meth* 1995; 180 : 181-91.

115. Doellgast GJ, Beard GA, Bottoms JD, Cheng T, Roh BH, Roman MG, *et al.* Enzyme-linked immunosorbent assay and enzyme-linked coagulation assay for detection of *Clostridium botulinum* neurotoxins A, B, and E and solution-phase complexes with dual-label antibodies. *J Clin Microbiol* 1994; 32 : 105-11.

116. Rach P, Perrelle S, Dilasser F, Grout J, Dargaingnarat C, Botella L, *et al.* Detection by PCR-enzyme-linked immunosorbent assay of *Clostridium botulinum* in fish and environmental samples from a coastal area in northern France. *Appl Environ Microbiol* 2002; 68 : 5870-6.

117. Hallis B, James BAF, Shone CC. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. *J Clin Microbiol* 1996; 34 : 1934-8.

118. Schmidt JJ, Stafford RG. Fluorogenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. *Appl Environ Microbiol* 2003; 69 : 297-303.

119. Ferreira JL, Handy MK, McCay SG, Baumstark BR. An improved assay for identification of type A *Clostridium botulinum* using the polymerase chain reaction. *J Rapid Methods Automat Microbiol* 1992; 1 : 293-9.

120. Campbell KD, Collins MD, East AK. Gene probes for identification of the botulinum neurotoxin gene and specific identification of neurotoxin types B, E and F. *J Clin Microbiol* 1993; 31 : 2255-62.

121. Szabo EA, Pemberton JM, Desmarchelier PM. Detection of genes encoding botulinum neurotoxins types A to E by polymerase chain reaction. *Appl Environ Microbiol* 1993; 59 : 3011-20.

122. Szabo EA, Pemberton JM, Gibson AM, Eyles MJ, Desmarchelier PM. Polymerase chain reaction for detection of *Clostridium botulinum* type A, B, and E in food, soil, and infant feces. *J Appl Bacteriol* 1994; 76 : 539-45.

123. Fach P, Hauser D, Guillou JP, Popoff MR. Polymerase chain reaction for the rapid identification of *Clostridium botulinum* type A strains and detection in food samples. *J Appl Bacteriol* 1993; 75 : 234-9.

124. Hielm S, Hyytia E, Ridell J, Korkeala H. Detection of *Clostridium botulinum* in fish and environmental samples using polymerase chain reaction. *Int J Food Microbiol* 1996; 31 : 357-65.

125. Aranda E, Rodriguez MM, Asensio MA, Cordoba JJ. Detection of *Clostridium botulinum* types A, B, E and F in foods by PCR and DNA probe. *Lett Appl Microbiol* 1997; 25 : 186-90.

126. Lindstrom M, Keto R, Markkula A, Nevas M, Hielm S, Korkeala H. Multiplex PCR assay for detection and identification of *Clostridium botulinum* type A, B, E, and F in food and fecal material. *Appl Environ Microbiol* 2001; 67 : 5694-9.

127. Lin WJ, Johnson EA. Genome analysis of *Clostridium botulinum* type A by pulsed-field gel electrophoresis. *Appl Environ Microbiol* 1995; 61 : 4441-7.

128. Hielm S, Bjorkroth J, Hyytia E, Korkeala H. Genomic analysis of *Clostridium botulinum* group II by pulsed-field gel electrophoresis. *Appl Environ Microbiol* 1998; 64 : 703-8.

129. Hielm S, Bjorkroth J, Hyytia, E, Korkeala H. Ribotyping as an identification tool for *Clostridium botulinum* species causing human botulism. *Int J Food Microbiol* 1999; 47 : 121-31.

130. Aron SS, Schechter R, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, *et al.* Botulinum toxin as a biological weapon: Medical and public health management. *JAMA* 2001; 285 : 1059-70.

131. Siegel LS. Human response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme linked immunosorbent assay. *J Clin Microbiol* 1988; 25 : 2351-6.

132. Pittman PR, Hack D, Mangaifico J, Gibbs P, McKe KT Jr., Friedlander AM, *et al.* Antibody response to a delayed booster dose of anthrax vaccine and botulinum toxoid. *Vaccine* 2002; 20 : 2107-15.

133. Byrne MP, Smith LA. Development of vaccine for prevention of botulism. *Biochimie* 2000; 82 : 955-66.

134. Atassi MZ, Oshima M. Structure, activity and immune (T & B cell) recognition of botulinum neurotoxin. *Crit Rev Immunol* 1999; 19 : 219-60.

135. Lee JS, Pushko P, Parker MD, Dertzbaugh MT, Smith LA, Smith JF. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. *Infect Immun* 2001; 69 : 5709-15.

136. Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency and efficacy of botulinum neurotoxin type A binding domain from *Pichia pastoris* as a recombinant vaccine candidate. *Infect Immun* 1998; 66 : 4817-22.

137. Bennett AM, Perkins SD, Holley JL. DNA vaccination protects against botulinum neurotoxin type F. *Vaccine* 2003; 21 : 3110-7.

138. Zeng M, Xu Q, Elias M, Pichichero ME, Simpson LL, Smith LA. Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectorized vaccine. *Vaccine* 2007; 25 : 7540-8.

139. Xu Q, Pichichero ME, Simpson LL, Elias M, Smith LA, Zeng M. An adenoviral vector-based mucosal vaccine is effective in protection against botulism. *Gene Ther* 2009; 16 : 367-75.

140. Tackett CO, Shandera WX, Mann JM, Hargrett, NT, Blake PA. Equine antitoxin use and other factors that predict outcome in type A foodborne botulism. *Am J Med* 1984; 76 : 794-8.
141. Francisco AM, Arnon SS. Clinical mimics of infant botulism. Pediatrics 2007; 119: 826-8.

142. Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev 1980; 44: 419-48.

143. Black RE, Gunn RA. Hypersensitivity reactions associated with botulinum antitoxin. Am J Med 1980; 69: 567-70.

144. Arnon SS. Creation and development of the public service orphan drug human botulism immune globulin. Pediatrics 2007; 119: 785-9.

145. Jing Z, Miao WY, Ding FH, Meng JY, Ye HJ, Jia GR, et al. The effect of toosendanin on monkey botulism. J Tradit Chin Med 1985; 5: 29-30.

146. Shi YL, Wang ZF. Cure of experimental botulism and antibioticism effect of toosendanin. Acta Pharmacol Sin 2004; 25: 839-48.

147. Shi YL, Li MF. Biological effects of toosendanin, a triterpenoid extracted from Chinese traditional medicine. Prog Neurobiol 2007; 82: 1-10.

148. Fischer A, Nakai Y, Eubanks LM, Clancy CM, Tepp WH, Pellett S, et al. Bimodal modulation of the botulinum neurotoxin protein-conducting channel. Proc Natl Acad Sci USA 2009; 106: 1330-5.

149. Boldt GE, Kennedy JP, Janda KD. Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett 2006; 8: 1729-32.

150. Burnett JC, Ruthel G, Stegmann CM, Panchal RG, Nguyen TL, Hermone AR, et al. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem 2007; 282: 5004-14.

151. Kumaran D, Rawat R, Ludivicco ML, Ahmed SA, Swaminathan S. Structure and substrate based inhibitor design for Clostridium botulinum neurotoxin serotype A. J Biol Chem 2008; 283: 18883-91.

152. Silvaggi NR, Wilson D, Tziori S, Allen KN. Catalytic features of the botulinum neurotoxin A light chain revealed by high resolution structure of an inhibitory peptide complex. Biochemistry 2008; 47: 5736-45.

153. Cai S, Singh BR. Strategies to design inhibitors of Clostridium botulinum neurotoxins. Infectious Disorders - Drug Targets 2007; 7: 47-57.

154. Tok JB, Fischer NO. Single microbead SELEX for efficient ssDNA aptamer generation against botulinum neurotoxin. Chem Commun 2008; 28: 1883-5.

155. Zhang P, Ray R, Singh BR, Li D, Adler M, Ray P. An efficient drug delivery vehicle for botulism countermeasure. BMC Pharmacol 2009; 9: 12.

156. Scott AB. Botulinum injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980; 87: 1044-9.

157. Scott AB. Botulinum toxin injection of eye muscles to correct strabismus. Trans Am Ophthalm Soc 1981; 79: 734-70.

158. Lew MF, Adornato BT, Duane DD, Dykstra DD, Factor SA, Massey JM, et al. Botulinum toxin type B: A double-blind, placebo-controlled, safety and efficacy study in cervical dystonia. Neurology 1997; 49: 701-7.

159. Mezaki T, Kaji R, Kohara N, Fuji H, Katayama M, Shimizu T, et al. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: A double-blind, controlled study. Neurology 1995; 45: 506-8.

160. Maselli RA, Burnett ME, Tonsgard JH. In vitro microelectrode study of neuromuscular transmission in a case of botulism. Muscle Nerve 1992;15:273-6.

161. Ranoux D, Gury C, Fondarai J, Mas JL, Zuber M. Respective potencies of Botox® and Dysport®: A double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002; 72: 459-62.

162. Sampaio C, Costa J, Ferreira JJ. Clinical comparability of marketed formulations of botulinum toxin. Mov Disord 2004; 19: S129-36.

163. Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 2007; 29: 1761-8.

164. Jost WH, Blumel J, Grafè S. Botulinum neurotoxin type A free of complexing proteins (Xeomin) in focal dystonia. Drugs 2007; 67: 669-83.

165. Jankovic J. Botulinum toxin therapy for cervical dystonia. Neurotox Rev 2006; 9: 145-8.

166. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, et al. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review). Neurology 2008; 70: 1691-8.

167. Frei K, Truong DD, Dressler D. Botulinum toxin therapy of hemifacial spasm: comparing different therapeutic preparations. Eur J Neurol 2006; 13: 30-5.

168. Naumann M, Jost W. Botulinum toxin treatment of secretory disorders. Mov Disord 2004; 19: S137-41.

169. Brin MF, Lyons KE, Doucette J, Adler CH, Caviness JN, Cornella CL, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology 2001; 56: 1523-8.

170. Lang AM. Botulinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil 2003; 84: S69-73.

171. Schurch B, Schmid DM, Knapp PA. An update on the treatment of detrusor-sphincter dyssynergia with botulinum toxin type A. Eur J Neurol 2007; 6: S83-9.

172. Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol 2007; 52: 13-31.

173. Flynn TC. Update on botulinum toxin. Semin Cutan Med Surg 2006; 25: 115-21.

174. Madalinski M, Chodorowski Z. Why the most potent toxin may heal anal fissure. Adv Ther 2006; 23: 627-34.

175. Ghazizadeh S, Nikzad M. Botulinum toxin in the treatment of refractory vaginismus. Obstet Gynecol 2004; 104: 922-5.

176. Thwaini A, Shergill I, Radhakrishnan S, Chinegwundoh F, Thwaini H. Botox in urology. J Int Urogynecol 2006; 17: 536-40.

177. Song PC, Schwartz J, Blitzer A. The emerging role of botulinum toxin in the treatment of temporomandibular disorders. Oral Dis 2007; 13: 253-60.

178. Jankovic J, Brin MF. Botulinum toxin: Historical perspective and potential new indications. Muscle Nerve 1997; 20: S129-45.
179. Blitzer A, Binder WJ, Aviv JE, Keen MS, Brin MF. The management of hyperfunctional facial lines with botulinum toxin. A collaborative study of 210 injection sites in 162 patients. *Arch Otolaryngol* 1997; 123: 389-92.

180. Anderson ER Jr. Proper dose, preparation, and storage of botulinum neurotoxin serotype A. *Am J Health Syst Pharm* 2004; 61 (22 Suppl 6): S24-29.

181. Hexsel D, Dal’Forno T, Hexsel C, Do Prado DZ, Lima MM. A randomized pilot study comparing the action halos of two commercial preparations of botulinum toxin type A. *Dermatol Surg* 2008; 34: 52-9.

182. Singh BR, Thirunavukkarasu N, Ghosal K, Ravichandran E, Kukreja R, Cai S, et al. Clostridial neurotoxins as a drug delivery vehicle targeting nervous system. *Biochimie* 2010; 92: 12532-9.

183. Chaddock JA, Purkiss JR, Duggan MJ, Quinn CP, Shone CC, Foster KA. A conjugate composed of nerve growth factor coupled to a non-toxic derivative of *Clostridium botulinum* neurotoxin type A can inhibit neurotransmitter release *in vitro*. *Growth Fact* 2000; 18: 147-55.

184. Simpson LL. Identification of the characteristics that underlie botulinum toxin potency: Implications for designing novel drugs. *Biochimie* 2000; 82: 943-53.

*Reprint requests:* Dr Ram Kumar Dhaked, Scientist ‘D’, Biotechnology Division, Defence Research & Development Establishment Jhansi Road, Gwalior 474 002, India

e-mail: ramkumardhaked@hotmail.com